TSXV - Delayed Quote CAD

Avivagen Inc. (VIV.V)

0.0050 0.0000 (0.00%)
At close: March 5 at 9:30 AM EST

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
NameTitlePayExercisedYear Born
Mr. G. F. Kym Anthony CEO & Vice Chairman 361.06k -- 1956
Dr. Graham Burton Ph.D. Co-Founder, Chief Scientific Officer & Director 126.33k -- --
Mr. Ira Levy Interim Chief Financial Officer 120.38k -- --
Dr. James Nickerson Ph.D. President and Executive VP of Business Development & Product Innovation -- -- --
Mr. Drew Basek Director of Investor Relations -- -- --
Ms. Tracy Gillett BVSC Director of Companion Animal & Marketing Manager -- -- --

Avivagen Inc.

100 Sussex Drive
Ottawa, ON K1A 0R6
Canada
613-702-2908 https://www.avivagen.com
Sector: 
Healthcare

Description

Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.

Corporate Governance

Avivagen Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • May 25, 2017
    Dividend Date

Upcoming Events

Apr 25, 2024 - Apr 27, 2024
Avivagen Inc. Earnings Call

Related Tickers